Terazosin
Terazosin. Selective α1-adrenergic blocker — same vascular + prostate smooth muscle relaxation as doxazosin. Approved for BPH + hypertension.… Oral half-life 12 h.
Selective α1-adrenergic blocker — same vascular + prostate smooth muscle relaxation as doxazosin. Approved for BPH + hypertension. Required to be uptitrated from low doses to avoid first-dose syncope. Off-label research interest as a senolytic-like + lifespan compound (Drosophila + mouse data).
PK: F 0.9 WAS LIFTED FROM A PROTEIN-BINDING FIGURE — the source sentence is that terazosin is "90 to 94 percent ... bound to plasma proteins", while the same abstract says the drug is "completely and consistently bioavailable", so F is pinned to 1. This is one of two such collisions found in this batch, the other being tiagabine at 96%. Half-life 12 h is verbatim and stands. V 28 L was the midpoint of a stated "25 to 30 L"; the stated lower endpoint is now carried. ka 1.2 /h dropped, sitting beside a stated time to peak of one to two hours.
Pharmacokinetics
- Oral — t½ 12 h · F 100% · Vd 25 L
Sources: PMID:2872802